Skip to content
10-K

Annual Report

Citius Pharmaceuticals, Inc. CTXR

0001213900-25-125333

← back to feed
Filed
Dec 23, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Sep 30, 2025 11.07M sh
Shares Diluted FY 2025 · Sep 30, 2024 6.73M sh
Operating Cash Flow FY 2025 · Sep 30, 2025 −$26.55M
Operating Cash Flow FY 2025 · Sep 30, 2024 −$28.2M
Cash And Equivalents FY 2025 · Sep 30, 2025 $4.25M
Cash And Equivalents FY 2025 · Sep 30, 2024 $3.25M
Stockholders Equity FY 2025 · Sep 30, 2025 $67.55M
Stockholders Equity FY 2025 · Sep 30, 2024 $70.08M
Current Liabilities FY 2025 · Sep 30, 2025 $44.91M
Current Liabilities FY 2025 · Sep 30, 2024 $35.81M
Total Liabilities FY 2025 · Sep 30, 2025 $53.41M
Total Liabilities FY 2025 · Sep 30, 2024 $42.55M
Current Assets FY 2025 · Sep 30, 2025 $27.93M
Current Assets FY 2025 · Sep 30, 2024 $14.22M
Total Assets FY 2025 · Sep 30, 2025 $130.94M
Total Assets FY 2025 · Sep 30, 2024 $116.65M
Eps Diluted FY 2025 · Sep 30, 2025 −$3.38
Eps Diluted FY 2025 · Sep 30, 2024 −$5.97
Eps Basic FY 2025 · Sep 30, 2025 −$3.38
Eps Basic FY 2025 · Sep 30, 2024 −$5.97
Sga Expense FY 2025 · Sep 30, 2025 $18.53M
Sga Expense FY 2025 · Sep 30, 2024 $18.25M
Rd Expense FY 2025 · Sep 30, 2025 $9.16M
Rd Expense FY 2025 · Sep 30, 2024 $11.91M
Operating Income FY 2025 · Sep 30, 2025 −$38.53M
Operating Income FY 2025 · Sep 30, 2024 −$42M